Ketamine Troches vs. Intramuscular (IM) Injections: A Complete Comparison

Quick Answer: Troches vs Intramuscular Ketamine

Sublingual troches and intramuscular (IM) ketamine injections deliver the same drug but produce very different sessions. IM ketamine produces higher peak plasma levels with a sharper onset (typically in the range of 5 to 15 minutes) and a shorter, more intense experience -- almost always in a clinic. Troches are slower (onset in the 10 to 20 minute range), gentler, and held buccally for at-home sessions. IM is generally more clinically powerful per dose; troches trade some intensity for accessibility, lower cost, and the ability to dose at home.

Is ketamine more effective intramuscular or sublingual?

IM ketamine generally produces stronger and more reliable response than buccal troches per session, because bioavailability for IM is in the roughly 90+ percent range while buccal troches deliver in the 20 to 30 percent range. That said, troche programs can match overall results for many people when used across a full loading-plus-maintenance protocol, especially at lower cost and with at-home convenience.

What about IM vs subcutaneous (SC)?

IM and SC routes both bypass the gut and produce high bioavailability. SC ketamine has a slightly slower onset and somewhat smoother curve than IM and is used in some clinic protocols and research, but is far less common than IM or IV in routine US care. Neither route is used at home.

Which is cheaper, troches or IM?

Troches are typically much cheaper per month than IM, because IM requires in-clinic administration and monitoring. Most IM sessions run in the high-hundreds-per-session range, while a month of troche maintenance generally lands in the low-hundreds-of-dollars range total.

Can I switch from IM to troches?

Yes -- many programs transition stabilized IM patients to maintenance troches once acute loading is complete, both to lower cost and to enable at-home dosing. The transition is prescriber-supervised and the troche dose is selected to match clinical response, not to deliver the same milligrams as IM.

Overview

Ketamine troches and intramuscular (IM) ketamine injections occupy very different positions in the ketamine therapy spectrum. IM injections deliver a rapid, high-bioavailability dose in a clinical setting, while troches provide a gentler, at-home experience with lower bioavailability but far greater convenience and affordability for ongoing treatment.

Understanding the strengths and limitations of each helps patients and providers choose the right route for each phase of treatment. Our article on troches for maintenance vs. acute treatment explores when each approach is most appropriate — or determine whether combining both is the optimal approach.

How Each Route Works

Troches (Sublingual)

A compounded ketamine lozenge is placed under the tongue and allowed to dissolve over 15-30 minutes. Ketamine absorbs through the sublingual mucosa directly into systemic circulation, partially bypassing first-pass liver metabolism.

IM Injection

A measured dose of ketamine solution is injected into a large muscle — typically the deltoid (shoulder) or vastus lateralis (thigh). From the muscle tissue, ketamine rapidly diffuses into the surrounding capillary network and enters systemic circulation with near-complete absorption.

IM injections are typically administered by a clinician in a supervised setting, though some providers prescribe self-injection for at-home use (this is less common and requires specific training).

Pharmacokinetic Comparison

The bioavailability difference is substantial. A 200 mg troche delivers approximately 50-60 mg of ketamine to the bloodstream. An IM injection of just 70 mg delivers approximately 65 mg. This means IM dosing can be far more precise and lower in absolute milligrams while achieving equivalent or greater blood levels.

Clinical Setting and Supervision

IM: Typically Clinic-Based

Most IM ketamine is administered in clinical settings — ketamine clinics, psychiatrists' offices, or infusion centers. The session typically involves:

• Pre-session vital signs (blood pressure, heart rate)
• Clinician-administered injection
• 45-90 minutes of monitored recovery in a reclining chair or treatment room
• Post-session vital sign check
• Observation until the patient is ambulatory and cognitively clear
• Transportation home (patients cannot drive)

This level of supervision provides an additional safety layer, particularly valuable for new patients, higher doses, or those with comorbid medical conditions.

Troches: Home-Based

Troche therapy is designed for self-administration at home with provider oversight through periodic telehealth visits. The patient manages their own session environment, technique, and recovery. A support person present in the home is recommended but not always required.

Cost Comparison

Cost is one of the most significant differentiators:

For long-term maintenance therapy, the cost difference is dramatic and often determines which route is financially sustainable.

The Experience

IM Session Character

IM ketamine produces a faster, more intense onset. Patients often describe:

• Rapid transition from normal consciousness to altered state within 3-5 minutes
• More pronounced dissociative effects at equivalent blood levels
• A concentrated, immersive experience
• Potentially more vivid visual and emotional content
• A defined "peak" followed by relatively rapid resolution

The intensity can be therapeutically powerful — some patients and therapists believe the deeper dissociative state facilitates more profound psychological processing. However, it can also be overwhelming, particularly for first-time patients.

Troche Session Character

Troches produce a slower, more gradual arc:

• Gentle onset over 15-30 minutes allows the patient to ease into the experience
• Lower peak intensity at typical doses (due to lower bioavailability)
• A broader, more extended plateau of effects
• More time for emotional processing and introspection during the session
• Gentler resolution

Many patients find the troche experience more manageable and less anxiety-provoking, particularly as they become familiar with the medication.

Combining Both Routes

Some treatment protocols use both routes strategically:

• IM for acute loading: Initial treatment with IM injections to achieve rapid response, particularly for severe depression or acute crisis
• Troches for maintenance: Transitioning to at-home troches once initial response is established, maintaining gains affordably and conveniently

This combined approach leverages the strengths of each route — the clinical power of IM for initial breakthrough, the practical sustainability of troches for ongoing care.

Side Effect Comparison

Both routes share common ketamine side effects (dissociation, nausea, dizziness, elevated blood pressure). Route-specific differences:

• Troches: Bitter taste, oral numbness, slower onset means gradual side effect development
• IM: Injection site pain or bruising, faster onset means more abrupt side effect onset, potentially more intense dissociation at equivalent clinical doses

Nausea may be slightly less common with IM injection than troches because no drug passes through the gastrointestinal tract. However, the more intense dissociative effects of IM dosing can independently trigger nausea through vestibular mechanisms.

Who Benefits Most From Each Route

Troches are ideal for:

• Long-term maintenance therapy (cost and convenience are decisive)
• Patients who prefer home-based treatment
• Patients who have established a therapeutic response and need ongoing support
• Those who prefer a gentler, more gradual experience
• Patients in rural areas or without access to ketamine clinics

IM injections are ideal for:

• Initial treatment phase when rapid response is critical
• Patients with severe treatment-resistant depression or acute suicidal ideation
• Those who have not responded adequately to sublingual dosing
• Patients who prefer clinical supervision during sessions
• Those who want the most precise dosing possible

Key Takeaways

• IM injection achieves 93% bioavailability compared to 25-30% for troches — allowing lower absolute doses with more predictable blood levels.
• IM is typically clinic-based and significantly more expensive; troches are home-based and affordable for ongoing therapy.
• IM produces a faster, more intense experience; troches provide a gentler, more gradual session arc.
• Many patients benefit from combining both: IM for initial response, troches for maintenance.
• The choice between routes depends on treatment phase, financial considerations, proximity to clinics, and personal preference.

References

• Comparison of Ketamine Administration Routes — Systematic review comparing sublingual, oral, IM, and IV ketamine pharmacokinetics
• Intramuscular Ketamine for Treatment-Resistant Depression — Clinical evidence for IM ketamine in mood disorders
• StatPearls: Ketamine — Comprehensive reference on ketamine routes, dosing, and clinical applications
• NIMH: Ketamine Research — National Institute of Mental Health overview of ketamine therapy research